Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Chromosome 1q21 aberration is one of the most common cytogenetic abnormalities in multiple myeloma, and is considered an important prognostic factor. The present study analyzed the clinical relevance and prognostic impact of 1q21 gain in 194 patients with newly diagnosed multiple myeloma treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Jia, Shuangshuang, Chu, Yuping, Tian, Biao, Gao, Yaya, Zhang, Chunyan, Zheng, Yanhua, Jia, Weijing, Liu, Xiangxiang, Yuan, Ruifeng, Zhang, Na, Feng, Juan, Dong, Hongjuan, Xin, Xiaoli, Chang, Ziwei, Cao, Zhengcong, Tang, Hailong, Gao, Guangxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516279/
https://www.ncbi.nlm.nih.gov/pubmed/36185185
http://dx.doi.org/10.3389/fonc.2022.938550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516279/
https://www.ncbi.nlm.nih.gov/pubmed/36185185
http://dx.doi.org/10.3389/fonc.2022.938550

Ejemplares similares